Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALGS Aligos Therapeutics	$10.15 -0.5%	$8.19	$3.76 ▼ $46.80	$62.39M	2.77	169,301 shs	138,626 shs
ENGN enGene	$4.28 -0.9%	$3.64	$2.65 ▼ $11.00	$218.73M	-0.41	85,740 shs	66,155 shs
TIL Instil Bio	$25.83 -4.3%	$26.70	$10.80 ▼ $92.00	$174.35M	2.16	191,844 shs	30,151 shs
TNYA Tenaya Therapeutics	$1.07 -5.8%	$0.76	$0.36 ▼ $4.01	$176.83M	3.01	2.98 million shs	2.39 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALGS Aligos Therapeutics	0.00%	+32.47%	+11.72%	+85.45%	-26.25%
ENGN enGene	0.00%	+17.39%	+16.76%	+1.89%	-32.71%
TIL Instil Bio	0.00%	-3.05%	-14.83%	+28.40%	+99.19%
TNYA Tenaya Therapeutics	0.00%	-2.59%	+35.62%	+162.55%	-60.35%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALGS Aligos Therapeutics	4.4076 of 5 stars	3.5	4.0	4.8	3.4	1.7	0.0
ENGN enGene	3.1556 of 5 stars	3.5	5.0	0.0	1.1	2.5	0.6
TIL Instil Bio	2.8267 of 5 stars	3.5	4.0	0.0	0.0	3.3	0.6
TNYA Tenaya Therapeutics	2.6272 of 5 stars	3.5	1.0	0.0	1.5	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALGS Aligos Therapeutics	3.00	Buy	$50.00	392.85% Upside
ENGN enGene	3.00	Buy	$23.29	444.06% Upside
TIL Instil Bio	3.00	Buy	$119.00	360.70% Upside
TNYA Tenaya Therapeutics	3.00	Buy	$6.25	486.85% Upside

Current Analyst Ratings Breakdown

Latest ALGS, TNYA, ENGN, and TIL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ALGS Aligos Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
8/15/2025	TIL Instil Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$125.00 ➝ $125.00
8/7/2025	TNYA Tenaya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/5/2025	TIL Instil Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$125.00 ➝ $125.00
6/2/2025	TIL Instil Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALGS Aligos Therapeutics	$3.94M	15.84	N/A	N/A	($7.50) per share	-1.35
ENGN enGene	N/A	N/A	N/A	N/A	$5.35 per share	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	$25.96 per share	N/A
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	$1.07 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALGS Aligos Therapeutics	-$131.21M	-$19.79	N/A	N/A	N/A	-2,337.24%	-22.41%	-12.09%	11/5/2025 (Estimated)
ENGN enGene	-$55.14M	-$1.65	N/A	N/A	N/A	N/A	-32.60%	-28.26%	9/10/2025 (Estimated)
TIL Instil Bio	-$74.14M	-$12.92	N/A	N/A	N/A	N/A	-54.32%	-33.65%	11/12/2025 (Estimated)
TNYA Tenaya Therapeutics	-$111.13M	-$0.96	N/A	N/A	N/A	N/A	-93.83%	-75.66%	11/5/2025 (Estimated)

Latest ALGS, TNYA, ENGN, and TIL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/10/2025	Q3 2025	ENGN enGene	-$0.5084	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	TIL Instil Bio	-$1.72	-$3.24	-$1.52	-$3.24	N/A	N/A
8/6/2025	Q2 2025	ALGS Aligos Therapeutics	-$2.35	-$1.53	+$0.82	-$1.53	$0.43 million	$0.97 million
8/6/2025	Q2 2025	TNYA Tenaya Therapeutics	-$0.20	-$0.14	+$0.06	-$0.14	N/A	N/A
6/10/2025	Q2 2025	ENGN enGene	-$0.4768	-$0.51	-$0.0332	-$0.51	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALGS Aligos Therapeutics	N/A	N/A	N/A	N/A	N/A
ENGN enGene	$1.58	36.94%	N/A	N/A	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	N/A
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALGS Aligos Therapeutics	N/A	6.31	6.31
ENGN enGene	0.09	12.66	12.66
TIL Instil Bio	0.64	14.97	14.97
TNYA Tenaya Therapeutics	N/A	6.00	6.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALGS Aligos Therapeutics	60.43%
ENGN enGene	64.16%
TIL Instil Bio	60.56%
TNYA Tenaya Therapeutics	90.54%

Insider Ownership

Company	Insider Ownership
ALGS Aligos Therapeutics	4.80%
ENGN enGene	10.40%
TIL Instil Bio	47.20%
TNYA Tenaya Therapeutics	48.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALGS Aligos Therapeutics	90	6.15 million	5.86 million	No Data
ENGN enGene	31	51.11 million	45.79 million	N/A
TIL Instil Bio	410	6.75 million	3.61 million	No Data
TNYA Tenaya Therapeutics	110	162.98 million	83.69 million	Optionable

ALGS, TNYA, ENGN, and TIL Headlines

Recent News About These Companies

Faraz Ali Sells 14,533 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Stock

August 20, 2025 | marketbeat.com

Tenaya Therapeutics Reports Q2 2025 Financial Results

August 14, 2025 | tipranks.com

What is Leerink Partnrs' Estimate for TNYA FY2025 Earnings?

August 11, 2025 | marketbeat.com

Q3 EPS Estimate for Tenaya Therapeutics Lifted by Analyst

August 11, 2025 | marketbeat.com

Wall Street Zen Upgrades Tenaya Therapeutics (NASDAQ:TNYA) to Hold

August 10, 2025 | marketbeat.com

Tenaya Therapeutics (NASDAQ:TNYA) Given Buy Rating at Chardan Capital

August 8, 2025 | marketbeat.com

Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

August 8, 2025 | globenewswire.com

Tenaya Therapeutics reports Q2 EPS (14c), consensus (19c)

August 7, 2025 | msn.com

Tenaya Therapeutics (TNYA) Projected to Post Earnings on Thursday

August 7, 2025 | marketbeat.com

Tenaya (TNYA) Q2 Loss Narrows 59%

August 7, 2025 | fool.com

Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

August 6, 2025 | globenewswire.com

Equities Analysts Offer Predictions for TNYA Q1 Earnings

August 4, 2025 | marketbeat.com

Lifesci Capital Issues Negative Outlook for TNYA Earnings

August 4, 2025 | marketbeat.com

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Average Rating of "Buy" from Analysts

August 1, 2025 | marketbeat.com

Tenaya Therapeutics stock rises after positive safety reviews for heart gene therapies

July 30, 2025 | investing.com

Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed

July 30, 2025 | globenewswire.com

TNYA - Tenaya Therapeutics Inc Dividends - Morningstar

July 8, 2025 | morningstar.comM

TNYA - Tenaya Therapeutics Inc Trailing Returns - Morningstar

July 8, 2025 | morningstar.comM

Tenaya Therapeutics, Inc. (TNYA) Balance Sheet - Yahoo Finance

June 27, 2025 | finance.yahoo.com

Tenaya Therapeutics, Inc. (TNYA) Cash Flow - Yahoo Finance

June 27, 2025 | finance.yahoo.com

Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

May 16, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALGS, TNYA, ENGN, and TIL Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

$10.14 -0.06 (-0.54%)

As of 03:42 PM Eastern

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

enGene NASDAQ:ENGN

$4.28 -0.04 (-0.93%)

As of 03:45 PM Eastern

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Instil Bio NASDAQ:TIL

$25.83 -1.16 (-4.30%)

As of 03:47 PM Eastern

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

Tenaya Therapeutics NASDAQ:TNYA

$1.06 -0.07 (-5.75%)

As of 03:47 PM Eastern

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time